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Introduction: Postoperative anastomotic leaks remain a common and serious complication
of colorectal surgeries and are a major cause of mortality and morbidity of these procedures.
Anastomotic leaks (AL) have been extensively studied; however, there has been no signifi-
cant reduction in their prevalence over time. In addition, there is a significant economic
burden from AL attributed to the need for repeat surgery, radiologic intervention and
lengthened hospital stay. We conducted a comparative cost analysis of patients undergoing
colorectal surgery with anastomosis, with the application of fibrin sealant (FS) to the sutured
anastomosis versus not treating the sutured anastomosis with FS.
Methods: The deterministic decision-tree model was populated with clinical data including
operating room time, hospitalization days, occurrence of AL, need for revision surgery, blood
products and radiologic interventions to treat the AL in lower colorectal surgery.
A systematic literature review was conducted to identify appropriate studies with these
variables.
Results: The average cost per case treated lower colorectal surgery with fibrin sealant glue
10 mL Tisseel® and those not treated with a fibrin sealant after suturing the anastomoses was
€3233 and €4130, respectively, for resource expenses paid by the healthcare system. This
would suggest potential savings of €897 per surgery, achieved through the application of FS
to the sutured anastomosis for preventing AL following colorectal surgery.
Conclusion: Application of FS to the sutured anastomosis in lower colorectal surgery
resulted in a decrease in post-operative AL, and cost savings based on a reduction in
hospitalization days, a reduction needing: revision surgery, radiologic intervention and
blood products to treat AL.
Keywords: fibrin sealant, anastomoses, cost analysis, budget impact, colorectal surgery,
colorectal cancer
Background
Postoperative anastomotic leaks (AL) remain a common and serious complication of
lower colorectal surgeries, as they are a major cause of mortality andmorbidity of these
procedures. Anastomotic leaks have been extensively studied; however, it is unclear
whether there has been any significant reduction in their incidence over time.12,42 Leak
rates vary across anastomotic sites, ranging from 3% to 29% for the colon,3,8,17,24,43
and 8% to 41% for the rectum.22,42 In a study of elderly patients living in the
Netherlands, it was estimated that in patients undergoing colorectal surgery, patients
< 75-years and patients ≥ 75-years had approximately 7.4%AL rate post colon surgery.
Patients < 75-years undergoing rectal surgery had an AL rate of 11.4%, versus 8.1% in
the ≥ 75-years group.12 Patients developing AL have significant morbidity up to 56%11
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and poor functional outcomes such as poor bowel function
impacting digestion.38 AL following colorectal resection is
also reported to have a significant mortality rate of 6–22%.12
The economic burden of AL can be significant. Several
studies reported that postoperative AL results in prolonged
hospital stays, the need for radiologic interventions and
occasionally revision surgery, can have significant costs in
addition to their clinical importance.20,23,42 A previous cost
analysis demonstrated that the burden of AL per 1000
patients in the US was $28.6 million in hospitalization and
readmission costs.19 The costs are likely to be higher if
indirect productivity costs were taken into consideration.
There are different recommendations for preventing
AL; however, there is a lack of decisive suggestions backed
by clinical studies to identify clinical best practice.5 Some
of the recommendations include over-sewing across the
staple-line and the use of fibrin sealants. Currently, there
are differences in opinion among surgeons, where some opt
to use fibrin sealant over the anastomoses for rectal surgery,
while some do not use it. As such, there have been several
studies investigating fibrin sealant’s use in preventing ana-
stomotic leaks in rectal surgeries.4,20,23,31
Fibrin sealant consists of fibrinogen and thrombin,
loaded into two syringes with tips forming a common
port.39 This formulation was designed to mimic the natural
hemostasis and wound healing process and aid in closures
of surgical incisions.6 In Spain, fibrin-based biological
adhesives are authorized for use in clinical practice for
many indications for achieving hemostasis and tissue seal-
ing during the surgical treatment.31 Various studies have
suggested a relationship between fibrin sealant to seal over
sutured ileocolic and colocolic anastomosis.35 To study
treatment practices and resource allocations in this area,
we conducted a comparative cost analysis based on differ-
ences in outcomes following colorectal surgery, where FS
is used to seal over the anastomosis compared to no use of
sealant. A systematic literature search was performed and
studies reporting anastomotic leaks were reviewed to iden-




The economic evaluation of Tisseel® was based on
a systematic review of prospective, randomized compara-
tive efficacy studies in lower colorectal surgery. Relevant
outcomes including hospital resource use metrics were
identified and evaluated for use in the economic evaluation
comparing the use of fibrin sealant with no fibrin sealant.
Search Strategy
A systematic literature search of prospective and randomized
studies in which the economic impact of employment of
fibrin sealant in colorectal surgery was conducted, including
its impact on metrics such as hospital stay, surgical time,
presence of AL, reoperation need, use of blood products and
radiological interventions, to identify clinical studies report-
ing outcomes from colorectal surgery (rectal/rectum sur-
geries (between the caudal margin of the tumor and the
anal verge)) in which fibrin sealants were used as hemostatic
agent, compared standard of care applying PRISMA criteria
for use in our cost analysis.25 PubMed, Google Scholar,
Embase and Cochrane databases were searched, and 416
articles were found; 414 were discarded for different reasons
(see Figure 1.) This search was performed for the period
January 1, 1980 to June 6, 2018 using the following search
terms: colorectal cancer, anastomosis, rectal anastomosis,
colorectal surgery, rectum surgery, fibrin sealant, fibrin-
based biological adhesive, patients, cost analysis, cost-
utility analysis, cost, and Boolean terms such as OR and
AND. Comparative studies identified in peer-reviewed
manuscripts were reviewed to identify surgical outcomes.
Quality assessment was performed for included studies
using checklists provided by the National Heart, Lung, and
Blood Institute.30 Appendix A1-A3 includes search terms
and strategy.
Data Extraction
Identified studies were reviewed by two independent
reviewers. Discrepancies between reviewers were resolved
by a third-party adjudicator. The first author of each study
identified was contacted via email to obtain additional
unreported study outcomes. Studies not reporting appro-
priate outcomes necessary to perform a cost analysis (eg,
length of hospitalization, radiological intervention, etc.)
were excluded from this analysis.
Articles were excluded for reasons including inappropriate
results, non-English-language or not translatable, included
pediatric subjects, having outcomes which were not related
to AL, and if the study was not properly designed (eg, a case
study or study with no comparison). Four articles and three
studies were identified specific to Tisseel being used for rectal
anastomosis closure following lower colon resection. Of these,
only two studies were appropriate for use in a meta-analysis to
determine AL rate, as one study had inappropriately presented
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data and design, and one studywas found to be presenting data
from the same study.20,23 The other 18 studies were not
appropriate for a comparative cost analysis but were studied
qualitatively and are mentioned in the discussion.
Clinical Inputs
Two randomized studies were identified that reflect cur-
rent treatment practices for rectal resection patients with
anastomosis and included appropriate outcomes on which
to perform a cost analysis of fibrin sealant.23,31 The
Oliver et al study was chosen for use in the model as it
represents the Spanish population. A significant differ-
ence in AL rates of 18.8% and 52.5% for fibrin sealant
and controls, respectively, have previously been
reported.31 The revision rate input was also reported in
this study, whereby revision surgery was required in 2 of
16 (12.5%) patients receiving Tisseel, and 9 of 21
(42.9%) patients that received no fibrin sealant to close
the anastomoses.31
Clinical outcomes that were not reported in the Oliver
study were identified from other studies with a similar
patient population. Hospitalization lengths of 9 days and
9.5 days for Tisseel versus the cohort that did not receive
any fibrin sealant were found from the study by Kim
et al.20,23 The study reported by Angelini et al reported
estimates on bleeding during rectal surgeries which
employ fibrin sealant (0.5%) vs no sealant (0.7%).4
Cost Data Inputs
Costs for surgery and hospitalization for Spain were found in
a study by Ielpo et al, which provides average costs per rectal
resection surgery (€3506) and subsequent hospitalization
(€266 per day) for a sample of 113 patients.21 The cost of
RBC transfusion (€368) has been calculated and published
by Ribed-Sanchez et al33 Tisseel costs, of €341 for 10 mL
formulation which is the dose used in the rectal surgeries
conducted in both the Oliver and the Kim study23,31 was
provided by Baxter Spain. The cost of Tisseel includes the
disposable applicator and the fibrin sealant formulation. The
cost of radiologic interventions to treat leaks was found to be
€1045 in a published report by the managing director of
Navarra Health Service-Osasunbidea.29
Modeled Cost Analysis
An excel-based decision-tree model was developed to inves-
tigate the costs of using fibrin sealant (Tisseel, Baxter,
Westlake Village, CA) for preventing AL in colorectal sur-
gery. The model compares the costs of conducting the sur-
gery and using a sealant to seal over the sutured anastomoses,
versus using no sealant, and its effects on outcomes such as
AL, bleeding requiring transfusion, hospital length of stay,
radiologic intervention and the need for revision surgery. The
modeled cohort is based on patients with an average age of
64.3 years undergoing rectal resection surgery requiring rec-
tal anastomosis.31 The model used the previously mentioned
clinical and cost inputs to project the cost-differences for
Figure 1 PRIMSA flow diagram for colorectal anastomoses studies which com-
pared fibrin sealant used for sealing anastomoses.
Dovepress Panda et al
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choosing to apply Tisseel for sealing of rectal anastomoses
versus not using any sealant at all, for preventing potential
anastomotic leaks.
To explore uncertainty around our analysis, we per-
formed bootstrapping to the trial data reported from the
study by Oliver et al, to generate confidence intervals (CI)
from the average cost per case analysis. The simulated
larger sample populations were calculated by conducting
repeated sampling using bootstrapping to generate 500
samples from replications of the clinical trial data.9 The
approach is used to generate larger sampling of the ori-
ginal trial results which are then randomly drawn from
the sample to generate confidence intervals for the aver-
age cost per treatment intervention. Costs were then
applied to the bootstrapped samples and a mean cost
difference with a confidence interval is presented to
give a measure of the stability and range of this value.
This approach was taken over a sensitivity analysis as the
costs, eg, per day hospitalization cost, are the same in
both arms of our model; consequently, there would not be
valuable information gained from varying these
parameters.
Results
The disaggregated costs per person treated with fibrin
sealant and no fibrin sealant after suturing the anasto-
moses, for radiologic interventions, red blood cell (RBC)
transfusions, revision surgery and length of stay (LOS) in
the hospital are described in Table 1. Based on the pre-
valence of radiologic intervention adjusted for actual
leaks, we estimate that there is a €351 per case difference
between Tisseel versus no fibrin sealant. For the Tisseel
group, there is also a €1064 reduction in potential revision
surgeries necessitated from leaks and a reduction of €133
attributed to the lower number of hospitalization days.
There is a very small cost difference in red blood cell
transfusions between groups, with the Tisseel group hav-
ing a greater cost of approximately €1. The total cost
savings for the Tisseel group was €1208 after an invest-
ment cost of €341 per patient. The results presented here
are based on secondary data and are point estimates.
The clinical study on which we modeled costs used
a smaller sample size; therefore, we conducted
a bootstrapped permutation-based test (to generate 500
samples) for verification purposes. We bootstrapped indi-
vidual patient costs based on the values found in the
clinical trial and costs found in the literature for our cost
calculation and reported in Table 2.
We checked for equality of variances and found that
the variances were not equal. A t-test was run for samples
with unequal variances assumed, and we found that there
was a statistically significant difference in means of €1323
(95% confidence interval 95% CI: €1277 to €1370;
p = 0.000).
Discussion
The results are demonstrating the economic benefits of
preventing AL by using fibrin sealant in colorectal surgery.
However, it is important to consider the broader applicabil-
ity of these findings to other GI surgeries. AL is a common
complication in other types of anastomoses such as esopha-
gojejunal surgery and surgeries of the pancreas and biliary
tract. In a study that compared FS application after manual
and stapled anastomoses, the postoperative leak rate in
a study of 42 patients with gastrointestinal anastomosis
was found to be 25% with minor leaks in 32 colorectal
and esophagojejunal anastomoses prior to applying FS,
and there were no leaks after FS application.34 FS has also
been considered for preventing major complications such as
leaks and re-intervention in laparoscopic Roux-en-Y gastric
bypass (LRYGBP) surgeries. In a study of 320 patients (160
patients receiving FS treatment over gastrojejunal, jejuno-
jejunal anastomoses, and over mesenteric openings, vs 160
Table 1 Estimated Average Cost per Patient Treated with










RBC Transfusions €2 €2 €1
Revision Surgery €438 €1503 -€1064
LOS €2391 €2524 -€133
Total €3368 €4576 -€1208
Abbreviation: LOS, length of stay.
Table 2 Independent Samples t-Test Results for Bootstrapped
Data (Resampled 500 Times)






500 €872 €444 €20
Control 500 €2196 €277 €12
Panda et al Dovepress
submit your manuscript | www.dovepress.com
DovePress






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
control patients), there was a statistically significant higher
number of complications in the control group, and
a suggested benefit in treating with FS for reducing re-
interventions.37 The results of the literature search revealed
the amount of evidence for this specific area of surgery was
limited; however, FS has been compared with no treatment
of FS for closing anastomoses in other surgical sites. We
found 18 studies that compared Tisseel for the closing of
anastomoses versus not using FS. One of the identified
studies was for pancreaticoduodenectomy,28 and one was
for esophagojejunal anastomosis,18 while the other 16 stu-
dies were for different procedures in the upper colorectum,
including anal fistula repairs and laparoscopic gastric
bypass surgeries.1,2,7,10,13–16,19,26,27,32,36,37,40,41,44 Many of
these studies suggest a relationship between FS and
a reduction in leakages and other complications such as
bleeding. However, these studies were not powered to find
statistical significance in results. While some studies found
results that suggest no benefit32 most gives a muted recom-
mendation based on the fact that FS has no adverse effects,
is not time-consuming to apply, and may be effective in
preventing leaks and internal hernias.37
The type of surgery we analyzed is notable as there is
a dearth of studies on anastomoses of the lower colon,
perhaps due to the serious nature of leaks in the higher
colon. However, the consequences of leaks in the rectum
are still quite detrimental to patients and the treatments are
very costly. Our results suggest that in colorectal surgeries
requiring rectal anastomosis, the use of FS leads to cost-
savings by preventing the need for revision surgeries and
radiologic interventions related to AL. FS is a relatively
low-cost preventative intervention, which can prevent
costly revision surgery. It would be worth exploring
through more robust clinical studies, whether its use
results in the prevention of serious leaks requiring revision
surgery. It would also be worthwhile to have studies that
more transparently discuss the different alternatives to
treating leaks. There is a great focus on revision surgery
because it is the most serious and expensive reaction to
a leak; however, it is more likely that most leaks are
treated with a radiologic intervention. The literature search
found few studies that report incidence rates of the radi-
ologic intervention being used to treat leaks. This informa-
tion would have been useful to our economic study.
The results described here are based on a single rando-
mized controlled trial using a small sample conducted in
Spain where FS was shown to reduce anastomotic leaks.
To confirm this finding, additional clinical trials including
a larger sample size would be needed. Therefore, it is
important to understand how reflective the clinical data
used in the economic model described here are applicable
in other settings. In our search, we identified a case-control
study reported by Kim et al,23 comparing fibrin sealant
(1–2 mL) with no sealant in over 1000 cases of low
anterior resection for rectal cancer. In this study, it was
demonstrated that FS was an independent factor that pre-
dicted the prevention of AL. This study could have been
used to model outcomes in the study described here;
however, it was determined that using a European patient
population would be more appropriate for the main para-
meter of interest—anastomotic leaks—for this economic
assessment in Spain.
We recognize that extrapolating our results from dif-
ferent prospective studies carried out in various regions
(South Korea, and Spain) is not ideal. A publication with
a larger sample size which reports all outcomes of interest
would have been more appropriate to use with Spanish
cost data. However, our choice was made after conducting
a thorough review of the literature and determining that no
such studies were published. We also consulted with local
doctors to inquire about other sources of data and found
that, while there are some initiatives to collect this type of
data, nothing has been published.
Conclusion
We conclude that using FS on the anastomosis is a favorable
alternative to not treating the anastomosis during rectal
surgery. Choosing to use FS leads to an estimated cost
saving of €1208 per patient, after deducting the cost of the
FS (approximately €341). The studies suggest that for
a relatively low cost, lower rates of AL and other complica-
tions are found in groups treated with FS.
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